Emcure Pharmaceuticals launches weight loss drug; here's how shares are performing

Emcure Pharma share price: Shares of drug maker Emcure Pharmaceuticals were trading in the negative territory on Monday, December 22, despite the company announcing the launch of a medication for weight loss.

The stock settled 0.29% lower at ₹1,381 per share on the National Stock Exchange (NSE).

In an exchange filing, the pharma player said it has commercially launched Poviztra, a semaglutide injection, across India.

With this, Emcure became the first Indian firm to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s semaglutide injection for weight management.

Poviztra, which is available in strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg in a once-weekly pen device, will be priced starting at ₹8,790 per month (four weekly doses), it added.

Poviztra is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater in the presence of at least one weight-related comorbid condition –hypertension, type 2 diabetes mellitus, or dyslipidemia.

Poviztra is also indicated to reduce the risk of major adverse cardiovascular events in adults.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said, "India is facing a significant obesity crisis, having nearly 254 million people living with generalised obesity and an additional 351 million living with abdominal obesity. The introduction of Poviztra marks an important step in expanding equitable access to scientifically validated weight-management solutions. Through our strong distribution capabilities and pan-India reach, we aim to ensure that more patients can benefit from advanced therapies like semaglutide."

Emcure Pharmaceuticals had posted a 25.12% increase in its consolidated net profit to ₹243.46 crore in the latest September quarter, compared to ₹194.57 crore in the same period a year ago.

Revenue from operations surged 13.37% to ₹2,269.82 crore in Q2 FY26 as against ₹2,001.98 crore in the year-ago period.